Agios Pharmaceuticals Inc. (AGIO)
AGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidate
Agios gains global rights to cevidoplenib for ITP, adding a late-stage rare hematology asset with up to $1B U.S. peak sales potential.
Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare Hematology Transcript
Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare Hematology Transcript
AGIO Halts Tebapivat Development in Myelodysplastic Syndromes
Agios discontinues development of tebapivat in lower-risk MDS after a phase IIb study misses efficacy goals, shifting focus to a phase II SCD program.
Why Is Agios Pharmaceuticals (AGIO) Up 8.6% Since Last Earnings Report?
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock?
AGIO's Pyrukynd Gets Approval for Thalassemia in Europe
Agios wins EU approval for Pyrukynd in adult thalassemia patients, expanding the drug's reach as the only authorized therapy for a broad patient population.
Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances
Agios Pharmaceuticals NASDAQ: AGIO executives said the company is focused on advancing mitapivat across rare hematologic diseases, highlighting early launch traction in thalassemia and a recently submitted supplemental new drug application for sickle cell disease during a presentation at the 2026 RBC Capital Markets Global Healthcare Conference.
Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease
AGIO seeks FDA accelerated approval for mitapivat in sickle cell disease after mixed phase III data and a planned confirmatory study.
AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug Momentum
Agios shares jump 13% as Q1 revenues surge 138% on Aqvesme launch and Pyrukynd growth, while pipeline advances and SCD filing plans take shape.
Agios Pharmaceuticals, Inc. (AGIO) Q1 2026 Earnings Call Transcript
Agios Pharmaceuticals, Inc. (AGIO) Q1 2026 Earnings Call Transcript
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.69 per share versus the Zacks Consensus Estimate of a loss of $1.81. This compares to a loss of $1.55 per share a year ago.
Earnings Preview: Agios Pharmaceuticals (AGIO) Q1 Earnings Expected to Decline
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD
Agios Pharmaceuticals jumps 14% as it moves toward accelerated FDA approval for mitapivat in sickle cell disease after key regulatory feedback.
